Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume Increase – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw unusually-strong trading volume on Wednesday . Approximately 9,503 shares traded hands during trading, an increase of 117% from the previous session’s volume of 4,372 shares.The stock last traded at $17.80 and had previously closed at $18.45.

Analyst Ratings Changes

A number of research firms have commented on AAPG. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 price objective for the company. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus price target of $46.67.

Ascentage Pharma Group International Price Performance

The business’s fifty day simple moving average is $22.83 and its 200 day simple moving average is $25.31. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $24.72 million for the quarter. On average, analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds and other institutional investors have recently modified their holdings of AAPG. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at $96,000. ABC Arbitrage SA acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at $204,000. Citadel Advisors LLC acquired a new position in shares of Ascentage Pharma Group International during the third quarter valued at $383,000. Hsbc Holdings PLC acquired a new position in shares of Ascentage Pharma Group International during the second quarter valued at $391,000. Finally, XY Capital Ltd boosted its holdings in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the period.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.